All You Need to Know About LivaNova (LIVN) Rating Upgrade to Buy

LivaNova (LIVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Mar 5, 2026

Artisan International Small-Mid Fund Q4 2025 Performance Review

The portfolio meaningfully outperformed the MSCI EAFE Small Cap Growth Index but modestly lagged the blend MSCI ACWI ex USA SMID Index. Our portfolio, which has a structural growth orientation, has no exposure to these cyclical, capital-intensive and highly regulated market segments. On an individual company basis, Metso, Celcuity and LivaNova were the largest Q4 contributors.

Seeking Alpha • Mar 2, 2026

LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript

LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 25, 2026

LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2025 results and issued full-year 2026 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $360.9 million increased 12.1% on a reported basis and 9.5% on both a constant-currency and organic basis as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share of $0.56 and adjusted diluted earnings per share o.

Business Wire • Feb 25, 2026

LivaNova (LIVN) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for LivaNova (LIVN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Feb 25, 2026

LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates

LivaNova (LIVN) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.8 per share. This compares to earnings of $0.81 per share a year ago.

Zacks Investment Research • Feb 25, 2026

Three Global Leaders Near Buy Points With Earnings Ahead

Fabrinet reports on Monday.

Investors Business Daily • Feb 2, 2026

LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results on Wed., Feb. 25, 2026, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its fourth-quarter and full-year 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to.

Business Wire • Jan 20, 2026

LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

LivaNova to Present at J.P. Morgan Healthcare Conference in January

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive Officer of LivaNova, and Alex Shvartsburg, Chief Financial Officer, will participate in a fireside chat on Wed., Jan. 14, 2026, at 1:30 p.m. Pacific Standard Time. The discussion will be available to all interested parties who register to attend the webcast, w.

Business Wire • Dec 23, 2025